Twist Bioscience Corp (NASDAQ:TWST) saw an upside of 3.35% to close Friday at $20.34 after adding $0.66 on the day. The 5-day average trading volume is 843,060 shares of the company’s common stock. It has gained $21.16 in the past week and touched a new high 2 times within the past 5 days. An average of 945,290 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 1,025,386.
TWST’s 1-month performance is 0.05% or $0.78 on its low of $19.04 reached on 08/25/23. The company’s shares have touched a 52-week low of $11.46 and high of $40.50, with the stock’s rally to the 52-week high happening on 02/02/23. YTD, TWST has lost -14.57% or -$3.47 and has reached a new high 9 times. However, the current price is down -49.78% from the 52-week high price.
Insider Transactions
TWST stock investors last saw insider trading activity on May 10.Starovasnik Melissa A. (Director) most recently sold 1,732 shares at $26.45 per share on Feb 09. This transaction cost the insider $45,820. Director, JOHANNESSEN JAN, sold 1,732 shares at a price of $26.45 on Feb 09. Then, on Jan 04, Banyai William sold 292 shares at a price of $24.05 per share. This transaction amounted to $7,023.
Valuation Metrics
TWST stock has a beta of 1.29. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 4.96 while the price-to-book (PB) in the most recent quarter is 1.77.
Twist Bioscience Corp’s quick ratio for the period ended June 29 was 5.62, with the current ratio over the same period at 6.12. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.12, while the total debt to equity was 0.14. In terms of profitability, the gross margin trailing 12 months is 38.62%. The trailing 12-month EBITDA margin is -104.33% while for the period ending June 29, Twist Bioscience Corp’s operating margin was -92.72%. The firm’s gross profit as reported stood at $84.23 million against revenue of $203.56 million.
Earnings Surprise
For the quarterly period ending June 29 this year, Net income and sales went up compared to those figures reported in the previous quarter. Net income shrunk -5.44% to -$57.4 million, while revenue of -$59.16 million was -3.07% off the previous quarter. Analysts expected TWST to announce -$1.14 per share in earnings in its latest quarter, but it posted -$1.01, representing a 11.40% surprise. EBITDA for the quarter stood at more than -$52.29 million. TWST stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 152.78 million, with total debt at $93.03 million. Shareholders hold equity totaling $57.4 million.
Let’s look briefly at Twist Bioscience Corp (TWST) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 22 September was 39.96% to suggest the stock is trending Neutral, with historical volatility in this time period at 36.67%.
The stock’s 5-day moving average is $20.21, reflecting a -2.91% or -$0.61 change from its current price. TWST is currently trading +6.05% above its 20-day SMA, +64.43% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -12.97% and SMA200 by-26.68%.
Stochastic %K and %D was 9.86% and 9.81% and the average true range (ATR) pointed at 1.07. The RSI (14) points at 43.33%, while the 14-day stochastic is at 17.66% with the period’s ATR at 1.15. The stock’s 9-day MACD Oscillator is pointing at -1.04 and -1.85 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Twist Bioscience Corp (NASDAQ: TWST), Scotiabank launched coverage with a Sector outperform rating. Analysts offering their rating for TWST stock have a consensus rating for the stock as Overweight. Currently, 1 brokerage advisors rate TWST as a “sell,”, while 2 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 2 rates the stock as overweight while 4 have offered a “buy” rating.
